BIOGENETICS & TECH LIMITED
Executive Summary
Biogenetics & Tech Limited is facing financial distress marked by negative equity and working capital deficits, though recent profit signals some operational improvement. The company currently relies heavily on shareholder support to meet obligations, posing risks to liquidity and long-term viability. Focused efforts on improving cash flow, reducing reliance on owner loans, and strengthening profitability are critical to restoring financial health and ensuring sustainability.
View Full Analysis Report →Company Documents
| Date | Description |
|---|---|
| 28/07/2528 July 2025 New | Confirmation statement made on 2025-06-14 with no updates |
| 06/05/256 May 2025 | Amended total exemption full accounts made up to 2023-06-30 |
| 29/03/2529 March 2025 | Total exemption full accounts made up to 2024-06-30 |
| 14/08/2414 August 2024 | Confirmation statement made on 2024-06-14 with no updates |
| 30/06/2430 June 2024 | Annual accounts for year ending 30 Jun 2024 |
| 15/03/2415 March 2024 | Total exemption full accounts made up to 2023-06-30 |
| 03/08/233 August 2023 | Confirmation statement made on 2023-06-14 with no updates |
| 30/06/2330 June 2023 | Annual accounts for year ending 30 Jun 2023 |
More Company Information
Follow Company
- Receive an alert email on changes to financial status
- Early indications of liquidity problems
- Warns when company reporting is overdue
- Free service, no spam emails Follow this company